Starton Therapeutics (Starton Therapeutics) ROCE % : 0.00% (As of Jun. 2023)

View and export this data going back to 2050. Start your Free Trial

What is Starton Therapeutics ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Starton Therapeutics's annualized ROCE % for the quarter that ended in Jun. 2023 was 0.00%.

Starton Therapeutics ROCE % Historical Data

The historical data trend for Starton Therapeutics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Starton Therapeutics ROCE % Chart

Starton Therapeutics Annual Data

Trend

Mar21

Mar22

Mar23

ROCE %

-228.60

-925.85

Starton Therapeutics Quarterly Data
	Mar21	Dec21	Mar22	Jun22	Dec22	Mar23	Jun23
ROCE %	Get a 7-Day Free Trial			-	-	-	-	-

Starton Therapeutics ROCE % Calculation

Starton Therapeutics's annualized ROCE % for the fiscal year that ended in Mar. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Mar. 2023 )		(A: Mar. 2022 )		(A: Mar. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Mar. 2023 )		(A: Mar. 2022 )		(A: Mar. 2023 )
	=	-9.993	/	( ( (2.574 - 4.026)	+	(2.137 - 6.005) )	/ 2 )
	=	-9.993	/	( (-1.452	+	-3.868)	/ 2 )
	=	-9.993	/	-2.66
	=	375.68 %

Starton Therapeutics's ROCE % of for the quarter that ended in Jun. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Jun. 2023 )		(Q: Mar. 2023 )		(Q: Jun. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Jun. 2023 )		(Q: Mar. 2023 )		(Q: Jun. 2023 )
	=	-12.196	/	( ( (2.137 - 6.005)	+	(4.243 - 7.003) )	/ 2 )
	=	-12.196	/	( ( -3.868	+	-2.76 )	/ 2 )
	=	-12.196	/	-3.314
	=	0 %

(1) Note: The EBIT data used here is four times the quarterly (Jun. 2023) EBIT data.

Starton Therapeutics (NAS:STA) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Starton Therapeutics ROCE % Related Terms

Thank you for viewing the detailed overview of Starton Therapeutics's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Starton Therapeutics (Starton Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Starton Therapeutics Inc (NAS:STA) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

215 College Road, Suite No.300, Paramus, NJ, USA, 07652

Website

https://www.startontx.com

Starton Therapeutics Inc is a clinical-stage biotechnology company transforming standard-of-care therapies with proprietary continuous delivery technology, so people with cancer can receive continuous treatment to live better, and longer. Starton's proprietary continuous delivery technology can increase the efficacy of approved drugs, make them more tolerable, and expand their potential use.

Starton Therapeutics (Starton Therapeutics) Headlines

No Headlines